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ABSTRACT 
OBJECTIVES To analyze the distribution of HLA alleles and HLA microsatellite alleles in 
Croatian patients with testicular carcinoma, compare it with that of healthy controls and 
investigate whether the polymorphism within the HLA region could be associated with the 
development of testicular cancer.  
METHODS Genomic DNA was isolated from the peripheral blood of 24 patients with testicular 
germ cell tumors (TGCT). Patients and controls were typed for HLA class I and class II 
polymorphism by PCR-SSO method. Nine HLA microsatellites were analyzed by PCR and 
electrophoresis in an automated sequencer.  
RESULTS No significant deviation in the distribution of frequencies at HLA class I alleles was 
observed between patients and controls. Among HLA class II alleles, a statistically significant 
increase in frequency of HLA-DPB1*1701 allele was found among patients. The frequency of 
the HLA-DRB1*07-DQA1*0201-DQB1*0202 haplotype was increased in patients in 
comparison to the controls. Analysis of HLA microsatellites showed an increased frequency of 
D6S291-3 allele (pcorr=0.0455, OR=3.05) among patients.   
CONCLUSIONS The observed association of the disease and DPB1*1701 allele as well as with 
the D6S291-3 allele suggests that this part of the HLA region might be involved in the 
pathogenesis of TGCT. Our data provide a basis for further studies about the correlation between 
HLA region and testicular cancer.  
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INTRODUCTION 
 
Testicular germ cell tumors (TGCT) constitute one of the most common malignancies in 
men 15–40 years of age and account for 2% of all malignancies in men.1 The incidence is 3-10 in 
100,000 males per year in Western society, while the number of diagnosed males/patients in 
Croatia was 145 in 2008 (crude rate 6.8 in 100,000 male population)2. This represents an 
increase since the incidence in 2001 was 5.7 per 100,000. The predominant histological type of 
testicular cancer is germ cell carcinoma (90-95%). TGCTs are divided into two major subgroups 
based on histological findings: seminoma (30-60%) and non-seminoma germ cell tumor. 
Seminoma cases account for approximately half of all TGCTs and most frequently appear in the 
fourth decade of life. The remaining cases of TGCTs are composed of nonseminoma histology 
(embryonal cell carcinoma, yolk sac tumor, choriocarcinoma and teratoma) and frequently 
present in the third decade of life. Most nonseminomatous tumors are mixed (composed of two 
or more cell types of which seminoma may be a component). Seminoma tumors are also more 
sensitive to chemotherapy and radiotherapy than nonseminomatous TGCTs.3 The etiology of 
TGCT is still poorly understood. In addition to possible environmental predisposing factors such 
as radiation, smoking and drug use, the role of genetic factors in the development of TGCT has 
also been suggested. This claim is supported by the fact that familial and bilateral testicular 
carcinoma cases occur more frequently than expected by chance with the odds risk (OR) for 
brothers of TGCT patients ranging from 3 to 13.4-6 Genetic susceptibility is also reflected by an 
increased incidence of TGCT in persons with certain rare malformations of the urogenital system 
such as Down and Klinefelter syndromes.7 Furthermore, the age distribution of TGCT might 
suggest a genetic origin of the disease: the young age at onset of testicular neoplasms indicates a 
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role of important etiologic factors operating early in life, either in utero or shortly after birth. 
Finally, ethnic differences in the incidence of TGCT may point to a genetic component in the 
etiology of the disease. The highest incidence is observed in Caucasians from Northern Europe, 
while Africans have a universally low incidence of TGCT.8 
 Although only a few studies have documented the association between the TGCT and 
HLA region, a difference in distribution of HLA antigens in patients compared to healthy 
controls has been found. Studies report higher frequencies of antigens HLA-DR1 and HLA-DR5 
antigens in patients with seminoma, and increased frequencies of antigens HLA-DR5 and HLA-
DR7 antigens in patients with nonseminoma.9 These studies indicate a connection between HLA-
DR antigens and TGCT.  
Microsatellites (Msats) are repeats of a DNA base motif (1-6bp, mostly CA repeats) up to 
100 times; they are distributed throughout the genome. Many of them display a high 
polymorphism which is based upon a variable number of repeats. Such markers have also been 
described in the HLA region10 and a growing interest in their potential applications, particularly 
in disease association studies, is being expressed. Microsatellite instability has been observed in 
different carcinomas among which is testicular carcinoma where such an instability has a 
pathogenetic significance.11 
 In the present study we analyzed the distribution of HLA class I (A, B, C) and HLA class 
II (DRB1, DQA1, DQB1, DPB1) alleles in Croatian patients with testicular carcinoma and 
healthy controls. The second aim of this pilot study was to investigate whether the polymorphism 
of HLA microsatellites in the HLA central region could be associated with the development of 
testicular carcinoma.  
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MATERIAL AND METHODS 
 
Patients and controls 
A total of 24 unrelated patients treated from March 2004 to April 2005 at the Department 
of Urology, University Hospital Zagreb were included in the analysis. Patient’s characteristics 
are presented in table 1. Preoperative diagnosis was assessed by clinical examination, testicular 
ultrasound and preoperative level of tumor markers (alpha-fetoprotein, beta human chorionic 
gonadotropin, lactate dehydrogenase). After orchidectomy, histologic diagnosis was established 
by pathologists experienced in urological pathology. 
One hundred unrelated healthy individuals without any signs of the disease were 
analyzed as a control group for HLA class I and HLA class II polymorphisms while 170 
unrelated subjects comprised the control group for Msats analysis. They originate from different 
regions of Croatia and form a representative sample of the Croatian population. 
Samples of 5 ml peripheral blood with EDTA were taken from each patient as well as 
from the control subjects.  
 
DNA isolation 
Genomic DNA was isolated using NucleoSpin kit following the manufacturer’s protocol 
(NucleoSpin, Macherey-Nagel, Düren, Germany).  
HLA class I and class II typing 
Patients and controls were typed for HLA class I (A, B, C) and class II (DRB1, DQA1, 
DQB1, DPB1) polymorphism by the Polymorphism Chain Reaction – Sequence Specific Oligos 
(PCR-SSO) method using Innolipa kit (Innogenetics, Gent, Belgium). HLA class I 
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polymorphisms were typed at low resolution level (two digits), while HLA class II 
polymorphisms were determined at high resolution level except for the DRB1 locus. With this 
protocol we were able to determine 18 specificities at HLA-A, 41 specificities at HLA-B, 15 
specificities at HLA-C, 13 specificities at HLA-DRB1, 86 alleles at HLA-DQB1, 34 alleles at 
HLA-DQA1 and 98 alleles at DPB1.  
 
HLA microsatellite typing 
Nine HLA microsatellites (D6S291, D6S1014, D6S273, TNFa, TNFd, TNFb, D6S2793, 
STR_MICA, and D6S2927) were analyzed. The Msats were amplified using primers labeled 
with Cy5. The primer sequences were as previously published.12 Amplifications were performed 
in a volume of 15µl containing 50ng DNA, 2.5mM dNTPs, MgCl2 (concentration varied for each 
Msat), 5U of Taq polymerase, 1.0µl PCR buffer and 10pmol of each primer. The cycling 
parameters were as previously reported.13 After amplification, PCR products were run on a 6% 
polyacrylamide gel in an automated sequencer (ALFexpress, Amersham Pharmacia, Uppsala, 
Sweden). The assignment of alleles was performed using AlleleLocator software (Amersham 
Pharmacia), which calculates the length of fragments by comparison, to the internal size markers. 
In addition, ALFexpress sizer 200 bp was also used as standard. To further improve the precision 
of fragment length determination, homozygous cell lines from the 10th International 
Histocompatibility Workshop (IHW) (which were previously typed for tested Msats) were also 
amplified for investigated Msats and run on each gel as external controls. The following cell 
lines were used: AMALA, BTB, KAS011, KAS016, TAB089 and VAVY. 
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Statistics 
The frequency of HLA specificities as well as Msat alleles were determined by direct 
counting. The χ2 test was used to compare the expected and observed value of genotype 
sequences in order to confirm whether it satisfies the Hardy–Weinberg law. p values were 
corrected by Yates’ correction and the number of HLA or Msat alleles under investigation (pcorr). 
The OR was determined according to Woolf.14 
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RESULTS AND DISCUSSION 
 
The presence of HLA class I alleles in 24 patients with testicular carcinoma was 
determined. No significant deviation in the distribution of frequencies at HLA-A, HLA-B and 
HLA-C loci was found between TGCT patients and controls (data not shown). 
  The significance of differences in allele frequencies between two tested groups for HLA 
class II alleles was also evaluated (table 2). The frequency of HLA-DRB1*07, DRB1*11 and 
DQA1*0201 specificities was increased among patients compared to controls, but without 
statistical significance. Conversely, a significant increase in occurence of HLA-DQB1*0202 
(P=0.0313, OR=3.56) among patients was observed, but only before correction. This is not in 
concordance with the published data which indicated an increase in HLA-DQ4 antigen frequency 
as well as the increased frequency of HLA-DRB1*0405 and HLA-DQB1*0401 alleles among 
patients.15 Recently, a high-resolution genotyping study in TGCT patients indicated HLA-
DRB1*0410 (OR=3.26) as a susceptibility allele and HLA-DQB1*0602 as a candidate protective 
allele (OR=0.26) for TGCT.16 We did not find an association between these alleles and TGCT in 
our group of patients. It is also important to mention that difference in alleles associated with 
TGCT could be explained by a variation of DRB1*0405, DRB1*0410 as well as DQB1*0401 
allele frequencies in the Japanese and Croatian populations.  On the other hand, there was a 
statistically significant increase in the frequency of the HLA-DPB1*1701 allele among patients 
(P=0.0140, OR=17.9) in comparison to controls. To the best of our knowledge, this is the first 
report about association between DPB1 alleles and TGCT.  Analysis of haplotypic associations 
was also performed and 13 different haplotypic associations were observed among patients. The 
most frequent alleles in both the patient and the control groups were HLA-DRB1*11, HLA -
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DQA1*0505 and HLA-DQB1*0301. Haplotype HLA-DRB1*07-DQA1*0201-DQB1*0202 was 
increased in patients in comparison to that obtained for the control group (P=0.0313, OR=3.56). 
It should be taken into consideration that the DRB1*0701 allele is one of the frequent alleles of 
the HLA-DR53 group in the Croatian population and that it belongs to the same serological 
haplotype group as DRB1*04 alleles (mentioned before) associated with TGCT among Japanese. 
It can therefore be speculated that the same configuration of these HLA haplotypes can be a 
predisposition for TGCT. The very first studies performed two decades ago on this subject 
reported about the association between TGCT and DRB4 gene but not with any particular allele 
at that locus. However, in order to reach any definitive conclusion, it is necessary to perform a 
large population study with the aim of analyzing a possible existence of linkage disequilibrium 
between DRB1 alleles and DPB1 alleles. This would ensure determining which of the mentioned 
HLA loci (DRB1 or DPB1) is primarily associated with TGCT since there are currently only a 
few studies available about the extended HLA haplotypes that include HLA-DPB1 alleles.  
The next part of the study involved the analysis of the nine HLA microsatellites among 
TGCT patients and the controls. The differences in frequencies between these two tested groups 
were observed for 3 alleles. The increase in the frequency which remained statistically 
significant even after the correction of p value, was observed for the D6S291-3 allele 
(pcorr=0.0455) (table 3).   
Relative risk values for microsatellite alleles which demonstrated a significant association 
with TGCT were calculated.  The highest OR values were observed for the D6S2927-6 and 
D6S291-3 alleles (OR=8.30 and OR=3.05, respectively). A reasonable explanation for such a 
high value of OR for the D6S2927-6 allele with TGCT might be found in the fact that this 
D6S2927 allele is in linkage disequilibrium with some HLA-B alleles which are slightly more 
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present among patients. Study on the analysis of microsatellites in children with acute leukemia 
and Down's syndrome also reported about a potential role of the D6S291 microsatellite in the 
susceptibility to disease.  The authors of this study observed a significantly increased frequency 
of two alleles at the D6S291 locus in patients.17 This may suggest that the D6S291 locus might 
be a susceptibility locus in certain carcinomas. Research of head and neck squamous cell 
carcinomas also show that the D6S291 marker appears to be an informative disease marker since 
a high frequency of allelic loss was found on this locus.18  
On the base of our data, we can propose that the DPB1 locus or region around that HLA 
class II gene plays an important role in the genetic predisposition to TGCT. The confirmation for 
such a theory might also be the association with the D6S291-6 allele. Namely, the D6S291 
microsatellite locus is located near the DPB1 locus. However, it is essential to point out the need 
foe a DPB1-D6S191 linkage analysis to elucidate the existence of linkage disequilibrium 
between the alleles of these two neighboring loci within the HLA region. 
In general, a in the HLA region may provide tumor cells with an immune escape tumor 
phenotype. At the same time, microsatellite instability seems to be a late event associated with 
tumor progression. Most studies show that invasive carcinomas manifest more microsatellite 
instability than precursor lesions, suggesting progressive accumulation of microsatellite 
instability during tumor development. Because of those observations, it would be interesting to 
analyze not only peripheral blood from patients with TGCT but also the carcinoma tissue to 
check for the presence of microsatellite instability as well as loss of heterozygosity in this type of 
carcinoma. The D6S2927-1 allele (previous name of locus was C1_4_1) was observed as a 
potential risk factor for spondyloarthropathies in South India population, while authors from Iran 
reported about the association between D6S2927-2 allele and Behcet’s disease. Recently, 
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D6S2927 has also been implicated in the pathogenesis of Crohn’s disease and ulcerative colitis 
in different ethnic populations.  
The observed significantly higher frequency (before correction) of the STR_MICA-A5 
allele among patients with TGCT could be explained with linkage disequilibrium of this 
MICA_STR allele with different HLA-B alleles which have shown slightly higher frequencies 
among patients. At the same time, this microsatellite is involved in pathogenesis of different 
diseases such as psoriatic arthritis, ulcerative colitis, breast cancer and colorectal cancer.19, 20  
In the end, it is of interest to note that, although this microsatellite has shown association 
with numerous diseases in studies reported so far, we have not observed any correlation between 
D6S273 and TGCT. 20  
The possible role of the HLA region in TGCT development could result from the effects 
of the HLA variation on the immune response to carcinogenic factors, e.g. viruses that may be 
etiologically associated with the development of TGCT. The importance of the HLA system in 
regulating susceptibility to a growing number of neoplastic conditions as well as tumor 
development is becoming increasingly clear. An impaired immune system, genetically or 
acquired, favours carcinogenic factors.21 
CONCLUSION 
 
This is, to our knowledge, the first study which has shown an association between HLA-
DPB1 allele as well as HLA microsatellites and TGCT. Although the results of this pilot study 
need confirmation on a larger number of patients, they indicated the direction which future 
studies should undertake in the clarification of the role of these polymorphisms in the etiology of 
TGCT. 
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Table 1. Patient’s characteristics (n=24) 
 
Median age at diagnosis (range), 
years 
30 (21-60)  
Histologic type, %  
    Pure seminoma 50.0  
    Nonseminoma 50.0 
Bilateral testicular carcinoma, %  8.0 
TNM stage, %  
Low stage* 70.8 
High stage** 29.2 
TNM (tumor, node, metastasis) classification 2002; * N0, N1; **N2, N3, M1 
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Table 3. Msat alleles with significant differences between patients with testicular 
carcinoma (n=24) and healthy controls (n=170) 
 
 
Msat  ALLELE PATIENTS 
 
CONTROLS 
 
p pcorr OR 
D6S291 3 (204bp) 12 (50.00%) 42 (24.71%) 0.0065 0.0455 3.05 
       
STR_MICA A5 (182bp) 10 (41.67%) 33 (19.41%) 0.0282 n.s. 2.97 
       
D6S2927 6 (233bp) 4 (16.67%) 4 (2.35%) 0.0091 n.s. 8.30 
 
pcorr - corrected P value; OR- odds ratio; n.s.- not significant 
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